Golden State Equity Partners Biocryst Pharmaceuticals Inc Transaction History

Golden State Equity Partners

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	BUY	$4.98 - $6.77 $2,514 - $3,418	505 Added 4.62%	11,430 $68,000
Q1 2023 Jun 01, 2023	SELL	$7.94 - $11.84 $4,049 - $6,038	-510 Reduced 4.46%	10,925 $91.1 Million
Q1 2022 May 18, 2022	BUY	$11.56 - $19.76 $132,188 - $225,955	11,435 New	11,435 $186,000
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $132,188 - $225,955	-11,435 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$11.18 - $15.46 $127,843 - $176,785	11,435 New	11,435 $158,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

Stay updated on Golden State Equity Partners with notifications on news.